Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Olaf Witt

Showing results (31-40 of 242) with videos related to

Pageof 25
Sort By:
Future Medicinal Chemistry|August 31, 2016
Targeting histone deacetylase 8 as a therapeutic approach to cancer and neurodegenerative diseasesAlokta Chakrabarti, Jelena Melesina, Fiona R Kolbinger, et al.
Pediatric Blood & Cancer|December 13, 2017
Response in a child with a BRAF V600E mutated desmoplastic infantile astrocytoma upon retreatment with vemurafenibCornelis M van Tilburg, Florian Selt, Felix Sahm, et al.
Trends in Pharmacological Sciences|May 28, 2015
HDAC8: a multifaceted target for therapeutic interventionsAlokta Chakrabarti, Ina Oehme, Olaf Witt, et al.
International Journal of Cancer|December 13, 2007
Histone deacetylase inhibitor Helminthosporium carbonum (HC)-toxin suppresses the malignant phenotype of neuroblastoma cellsHedwig E Deubzer, Volker Ehemann, Frank Westermann, et al.
BMC Cancer|June 12, 2012
Experimental in vivo and in vitro treatment with a new histone deacetylase inhibitor belinostat inhibits the growth of pancreatic cancerDmitriy I Dovzhanskiy, Stefanie M Arnold, Thilo Hackert, et al.
Acta Oncologica (Stockholm, Sweden)|January 24, 2015
Treatment tolerance of particle therapy in pediatric patientsJuliane G Rieber, Kerstin A Kessel, Olaf Witt, et al.
Leukemia Research|March 3, 2006
Novel valproic acid derivatives with potent differentiation-inducing activity in myeloid leukemia cellsHedwig Deubzer, Barbara Busche, Gabi Rönndahl, et al.
Cancer Letters|June 6, 2009
Regulation of BIRC5 and its isoform BIRC5-2B in neuroblastomaIsabella Eckerle, Daniel Muth, Julia Batzler, et al.
The Journal of Pathology. Clinical Research|February 6, 2020
NTRK fusions in osteosarcoma are rare and non-functional eventsBaptiste Ameline, Karim H Saba, Michal Kovac, et al.
Plos Computational Biology|November 11, 2021
DNA methylation-based classifier and gene expression signatures detect BRCAness in osteosarcomaMaxim Barenboim, Michal Kovac, Baptiste Ameline, et al.
Pageof 25

Showing results (31-40 of 242) with videos related to

Sort By:
Pageof 25
Future Medicinal Chemistry|August 31, 2016
Targeting histone deacetylase 8 as a therapeutic approach to cancer and neurodegenerative diseasesAlokta Chakrabarti, Jelena Melesina, Fiona R Kolbinger, et al.
Pediatric Blood & Cancer|December 13, 2017
Response in a child with a BRAF V600E mutated desmoplastic infantile astrocytoma upon retreatment with vemurafenibCornelis M van Tilburg, Florian Selt, Felix Sahm, et al.
Trends in Pharmacological Sciences|May 28, 2015
HDAC8: a multifaceted target for therapeutic interventionsAlokta Chakrabarti, Ina Oehme, Olaf Witt, et al.
International Journal of Cancer|December 13, 2007
Histone deacetylase inhibitor Helminthosporium carbonum (HC)-toxin suppresses the malignant phenotype of neuroblastoma cellsHedwig E Deubzer, Volker Ehemann, Frank Westermann, et al.
BMC Cancer|June 12, 2012
Experimental in vivo and in vitro treatment with a new histone deacetylase inhibitor belinostat inhibits the growth of pancreatic cancerDmitriy I Dovzhanskiy, Stefanie M Arnold, Thilo Hackert, et al.
Acta Oncologica (Stockholm, Sweden)|January 24, 2015
Treatment tolerance of particle therapy in pediatric patientsJuliane G Rieber, Kerstin A Kessel, Olaf Witt, et al.
Leukemia Research|March 3, 2006
Novel valproic acid derivatives with potent differentiation-inducing activity in myeloid leukemia cellsHedwig Deubzer, Barbara Busche, Gabi Rönndahl, et al.
Cancer Letters|June 6, 2009
Regulation of BIRC5 and its isoform BIRC5-2B in neuroblastomaIsabella Eckerle, Daniel Muth, Julia Batzler, et al.
The Journal of Pathology. Clinical Research|February 6, 2020
NTRK fusions in osteosarcoma are rare and non-functional eventsBaptiste Ameline, Karim H Saba, Michal Kovac, et al.
Plos Computational Biology|November 11, 2021
DNA methylation-based classifier and gene expression signatures detect BRCAness in osteosarcomaMaxim Barenboim, Michal Kovac, Baptiste Ameline, et al.
Pageof 25